Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Epoetin alfa may stimulate red blood cell production to treat patients who have anemia following chemotherapy.
PURPOSE: Phase IV trial to study the effectiveness of epoetin alfa in treating chemotherapy-related anemia in women who have stage I, stage II, or stage III breast cancer.
Biological: epoetin alfa
Procedure: quality-of-life assessment
|Study Design:||Primary Purpose: Supportive Care|
|Official Title:||An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer|
|Study Completion Date:||April 2004|
OBJECTIVES: I. Determine the effectiveness and safety of epoetin alfa in patients receiving adjuvant chemotherapy for stage I, II, or III breast cancer. II. Determine the clinical outcomes in these patients receiving this drug.
OUTLINE: This is a multicenter study. Patients receive epoetin alfa subcutaneously once weekly for up to 24 weeks in the absence of unacceptable toxicity. Quality of life is assessed at baseline, at week 13, and at study completion.
PROJECTED ACCRUAL: A maximum of 2,500 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00022386
|Study Chair:||John A. Glaspy, MD, MPH||Jonsson Comprehensive Cancer Center|